Seoul Pharma Co., Ltd.
KKRX:0186801,870.00
KRW
-2.00
(-0.11%)
ISIN
KR7018680009
Return %
Stock
S&P 500
1Y
-40.73
14.39
3Y
-43.25
81.42
5Y
-73.85
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 132
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Cheongju South Korea
- IPO Date
- Aug 18, 2000
- Website
- seoulpharma.com
- Similar Companies
- Business
- Seoul Pharma Co., Ltd. is a South Korea-based pharmaceutical manufacturing company engaged in the research, development, production, and commercialization of finished dosage pharmaceutical products, health functional foods, and proprietary orally disintegrating film (ODF) drug delivery systems. Founded in 1976 as Seoul New Drug Industry and incorporated in 1985, the company is headquartered in Cheongju-si, Chungcheongbuk-do, South Korea, and is publicly traded on the KOSDAQ market under ticker 018680. The company operates under the controlling ownership of private equity firm Q Capital Partners via the 2018 QCP No. 13 Private Equity Fund and is managed under a co-Chief Executive Officer leadership structure. The company organizes its commercial operations across Prescription Pharmaceuticals (ETC), Over-the-Counter Medicines (OTC) and Consumer Healthcare, and Contract Development and Manufacturing (CDMO / OEM-ODM) segments. Seoul Pharma manufactures and distributes a broad range of pharmaceutical formulations, with a core product portfolio structured across multiple therapeutic areas: cardiovascular and circulatory agents, including Ator for hypertension, Crestin for hyperlipidemia, and Zarotan; gastrointestinal agents, including Axated and Seoul Famotidine for peptic ulcers and gastritis; central nervous system and cerebrovascular treatments, including Flavel for stroke prevention and recovery; anti-inflammatory and analgesic medications, including Zerocam and Mardi; respiratory and antitussive therapies, including Sebron A syrup; and metabolic and anti-obesity agents, including Weltmin and Fendigene. A core proprietary competency of Seoul Pharma is its SmartFilm technology platform, which produces orally disintegrating films (ODF) that dissolve rapidly on the tongue without water to enhance patient compliance, rapid onset, and dosing convenience for pediatric, geriatric, and dysphagic populations. Its ODF pharmaceutical and nutraceutical offerings include erectile dysfunction treatments, such as Vultis (sildenafil citrate) and tadalafil ODF; functional dietary supplement films, such as Daily Liposomal Glutathione films, Premium Red Ginseng immune films, Green Propolis oral care films, Plant-based Melatonin sleep aid films, Nicotinamide Mononucleotide (NMN) cellular health films, and Polydeoxyribonucleotide (PDRN) skin rejuvenation films; and specialized liquid suspensions, such as Aliver BCAA suspension for hepatic cirrhosis. Manufacturing is anchored at the company's automated, cGMP-grade production plant within the Osong Bio-Health Science Complex in Cheongju, supporting the production of ODFs, tablets, hard capsules, ointments, creams, and liquid syrups. In recent corporate and operational developments, Seoul Pharma has focused on financial restructuring, operational efficiency, and commercial diversification following its acquisition by Q Capital Partners. The company has transitioned executive governance to a co-CEO management system and consolidated its primary manufacturing capabilities into its cGMP-certified Osong facility. To drive top-line expansion and capitalize on its patented SmartFilm delivery technology, Seoul Pharma has strategically scaled its B2B original equipment manufacturing (OEM) and original design manufacturing (ODM) operations, securing manufacturing contracts for oral thin-film health functional foods with domestic and international consumer brands. Geographically, the company continues to advance its global export footprint across Southeast Asia (including Vietnam, Hong Kong, the Philippines, and Taiwan), the Middle East, and Latin America through distribution and supply agreements with multinational pharmaceutical partners such as Pfizer and Sandoz, while continuously expanding its next-generation functional film pipeline with newly commercialized liposomal and bioactive nutraceutical lines.